The Food and Drug Administration (FDA) has approved the first drug to treat children with SLE.
The agency said in a statement on its website that the new drug is called Benlyst Benlyst, which is a vein injection.
She added that SLE is a serious chronic immune disease that causes inflammation and damage to various tissues and organs in the body.
The disease occurs in the form of a red rash on the cheeks and on the bridge of the nose and inflammation in many organs and organs of the body.
The FDA noted that this was the first time the FDA had approved the treatment of children with SLE. In 2011, it approved the same drugs but treated adults with this disease.
FDA approval came after a study of 93 children with lupus erythematosus and 52 weeks of treatment.
The results showed that children who received this medicine are less likely to develop skin rash than their placebo counterparts.
And the most common side effects of this drug, the Commission noted that it included nausea, diarrhea, and fever.
The word lupus is caused by the occurrence of lesions on the skin of signs of bite and is a rare feature on the skin, especially for this disease.
According to the authority, the incidence of children with lupus erythematosus is rare, but when diagnosed, affects diseased members such as the kidneys and the central nervous system.
As a result of this disease, children with lupus are more likely to have increased organ damage and complications.